Gregory Kuehn's guest appearances

Gregory Kuehn

Finding Genius Podcast

FutureTech Podcast

Laura Potterat

Marc Guell

Paul Turner

Jan Vijg

Eleftherios Mylonakis

Cory Kidd

Charles C.J

Helius Medical Technologies

Patrick McKeown

Michael G. Surette

Katelyn Parsons

John Tucker

Jake Kushner

Erik Gunther

Kim Kush

OwlTail

In this podcast, Gregory Kuehn, President and COO of Prescient Metabiomics, talks about his company’s innovative work in colorectal cancer treatment, as well as their development of a stool test for cancer. Kuehn earned his MBA from the University of Colorado, and a BS from the College of William and Mary in molecular biology as well as computer science. Kuehn discusses Prescient Metabiomics’ work researching how the microbiome can be used to predict or associate with various diseases. Kuehn explains their mission at Metabiomics, a pioneer in the development of human microbiome and advanced metagenomic technology. Prescient Metabiomics’ innovative and important research has lead to the development of a non-invasive stool test for the early detection of colon polyps and colorectal cancer. Their developments are based on intensive examination of the human gut microbiome. Kuehn provides an overview of their work in inflammatory bowel disease that eventually moved them to research methods to possibly prevent colon cancer. Kuehn discusses the microbiome in detail, explaining the complex relationships that the microbiome has with the human body overall. He explains biomarkers, discusses toxins, and gives his thoughts on the functional relationship between the gut microbiome and human health in general. In this podcast: Cancer development, and early predictors How the microbiome can help provide insight into possible future diseases Cancer detection / stool tests

In this podcast, Gregory Kuehn, President and COO of Prescient Metabiomics, talks about his company’s innovative work in colorectal <a href="https://www.futuretechhealth.com/podcasts/approaches-to-medicine-oscar-sierra-l-ac-of-buckhead-acupuncture-chinese-medicine-and-acupuncture-for-better-health/" rel="nofollow" target="_blank">cancer treatment</a>, as well as their development of a stool test for cancer. Kuehn earned his MBA from the University of Colorado, and a BS from the College of William and Mary in molecular biology as well as computer science. Kuehn discusses Prescient Metabiomics’ work researching how the microbiome can be used to predict or associate with various diseases. Kuehn explains their mission at Metabiomics, a pioneer in the development of human microbiome and advanced metagenomic technology. Prescient Metabiomics’ innovative and important research has lead to the development of a non-invasive stool test for the early detection of colon polyps and colorectal cancer. Their developments are based on intensive examination of the human gut microbiome. Kuehn provides an overview of their work in inflammatory bowel disease that eventually moved them to research methods to possibly prevent colon cancer. Kuehn discusses the microbiome in detail, explaining the complex relationships that the microbiome has with the human body overall. He explains biomarkers, discusses toxins, and gives his thoughts on the functional relationship between the gut microbiome and human health in general. In this podcast: Cancer development, and early predictors How the microbiome can help provide insight into possible future diseases Cancer detection / stool tests

Cancer & the Human Microbiome – Gregory Kuehn

Gregory Kuehn, MBA, President and COO of Prescient Metabiomics, formerly Metabiomics, discusses their innovative work in colorectal cancer treatment and the development of an advanced stool test for cancer. Kuehn holds an MBA from the University of Colorado and a BS from the College of William and Mary in molecular biology and computer science. Kuehn talks about their advanced work studying the microbiome to predict or associate with disease. Kuehn discusses their work at Prescient Metabiomics, a pioneer in the development of human microbiome and metagenomic technology. Their groundbreaking research has lead to the development of a non-invasive stool test for the early detection of colon polyps as well as colorectal cancer based on advanced examination of the human gut microbiome. Kuehn talks in-depth about their early work in inflammatory bowel disease, that led them to their current work studying how to prevent colon cancer. Kuehn discusses the detail that they have gone into studying the microbiome, looking at the complex relationships that the microbiome has with the entire body. He talks about biomarkers, toxins, and the functional relationship between the gut microbiome and human health. The cancer prevention researcher talks in detail about the various hypotheses that exist in their area of research, and why colon cancer has persisted. And Kuehn explains carcinogenesis and the early screening options. In this podcast: The mechanisms of cancer development How the microbiome can potentially provide insight into disease development Stool tests for cancer, how do they work

Gregory Kuehn, MBA, President and COO of Prescient Metabiomics, formerly Metabiomics, discusses their innovative work in colorectal <a href="https://www.futuretechpodcast.com/podcasts/combatting-cancer-charles-j-meakin-md-mha-medical-director-care-oncology-clinic-usa-finding-new-ways-to-fight-cancer-combinations-of-drugs-and-rethinking-treatment/" rel="nofollow" target="_blank">cancer treatment</a> and the development of an advanced stool test for cancer. Kuehn holds an MBA from the University of Colorado and a BS from the College of William and Mary in molecular biology and computer science. Kuehn talks about their advanced work studying the microbiome to predict or associate with disease. Kuehn discusses their work at Prescient Metabiomics, a pioneer in the development of human microbiome and metagenomic technology. Their groundbreaking research has lead to the development of a non-invasive stool test for the early detection of colon polyps as well as colorectal cancer based on advanced examination of the human gut microbiome. Kuehn talks in-depth about their early work in inflammatory bowel disease, that led them to their current work studying how to prevent colon cancer. Kuehn discusses the detail that they have gone into studying the microbiome, looking at the complex relationships that the microbiome has with the entire body. He talks about biomarkers, toxins, and the functional relationship between the gut microbiome and human health. The cancer prevention researcher talks in detail about the various hypotheses that exist in their area of research, and why colon cancer has persisted. And Kuehn explains carcinogenesis and the early screening options. In this podcast: The mechanisms of cancer development How the microbiome can potentially provide insight into disease development Stool tests for cancer, how do they work

Testing for Cancer – Gregory Kuehn, MBA, President and COO of Prescient Metabiomics – Colon Cancer, the Microbiome, Testing

Gregory Kuehn is the co-founder and COO of Metabiomics, a company that has been developing tools and techniques for analyzing the human gut microbiome for the last 15 years. Their primary focus is on the early detection and prevention of colon cancer through the identification of colonic polyps, which are precursors to colon cancer. With the combination of carefully-controlled clinical trials and machine learning methods that view the entire microbial community in a stool sample, Metabiomics has developed a non-invasive test to predict the presence or absence of polyps in any given patient. Since analysis of the gut microbiome can also be used to characterize the general health of the lining of the gut, these tests will also be used as diagnostic tools for IBD and IBS. Metabiomics is developing several tests that will be available to patients through their primary care or gastroenterologist’s office. “It’s an exploding field, it’s kind of a paradigm shift in that we are looking at human health differently and we are starting to take the health of the microbial communities inside us and on our skin a lot more seriously,” says Kuehn. Kuehn also addresses how the gut microbiome is affected by diet, and how this correlates to high levels of colon cancer in certain regions of the world, and the complete absence of colon cancer in other parts of the world. Press play to learn more, and visit metabiomics.com.

Gregory Kuehn is the co-founder and COO of Metabiomics, a company that has been developing tools and techniques for analyzing the human gut microbiome for the last 15 years. Their primary focus is on the early detection and prevention of colon cancer through the identification of colonic polyps, which are precursors to colon cancer. With the combination of carefully-controlled clinical trials and machine learning methods that view the entire microbial community in a stool sample, Metabiomics has developed a non-invasive test to predict the presence or absence of polyps in any given patient. Since analysis of the gut microbiome can also be used to characterize the general health of the lining of the gut, these tests will also be used as diagnostic tools for IBD and IBS. Metabiomics is developing several tests that will be available to patients through their primary care or gastroenterologist’s office. “It’s an exploding field, it’s kind of a paradigm shift in that we are looking at human health differently and we are starting to take the health of the microbial communities inside us and on our skin a lot more seriously,” says Kuehn. Kuehn also addresses how the gut microbiome is affected by diet, and how this correlates to high levels of colon cancer in certain regions of the world, and the complete absence of colon cancer in other parts of the world. Press play to learn more, and visit <a href="http://metabiomics.com" rel="nofollow" target="_blank">metabiomics.com</a>.